The content on this site is intended for healthcare professionals only
Dr Follows speaks at the 'measuring success in indolent disease' session during BSH 2017 in Brighton, UK.
Follows discusses how to measure treatment success.
The content available here was filmed at a Roche Products Limited promotional symposium and contains discussion of Roche medicines.
KRdc as induction therapy shows improved OS for NDMM patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
Multiple myeloma in a resource constrained setting
